Key result
A circRNA-miRNA-mRNA regulatory network comprising two circRNAs, two miRNAs, and 30 mRNAs was identified as differentially expressed in hypertrophic cardiomyopathy and validated in a cellular model.
Why the study?
The biological activities of competitive endogenous RNAs (ceRNAs) in the pathophysiology and prognosis of hypertrophic cardiomyopathy remained largely to be investigated.
A novel circRNA-miRNA-mRNA regulatory network was identified in hypertrophic cardiomyopathy, highlighting potential biomarkers and therapeutic targets related to calcium channel release.
Hypothesis-generating for ceRNA networks in HCM; leaves open clinical utility pending functional validation.
BACKGROUND: Hypertrophic cardiomyopathy (HCM) is a grave hazard to human health. Circular RNA (circRNAs) and micro RNA (miRNAs), which are competitive endogenous RNA, have been shown to play a critical role inHCM pathogenicity. However, to a great extent, the biological activities of ceRNA in HCM pathophysiology and prognosis remain to be investigated. MATERIALS AND METHODS: By analyzing the expression files in the Gene Expression Comprehensive (GEO) database, differentially expressed (DE) circRNAs, miRNAs, and mRNAs in HCM were identified, and the target molecules of circRNAs and miRNAs were predicted. The intersection of the differentially expressed RNA molecules and the expected target was then calculated, and a ceRNA network was subsequently constructed using RNA molecules. Using Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses, the potential etiology was elucidated. qPCR was used to validate a portion of the hub gene using Angiotensin II to generate a cell hypertrophy model. RESULTS: Three large-scale HCM sample datasets were extracted from the GEO database. After crossing these molecules with their expected targets, the circRNA-miRNA-mRNA network had two DEcircRNAs, two DEmiRNAs, and thirty DEmRNAs, compared to normal tissues. Functional enrichment analysis of GO and KEGG demonstrated that many of the HCM pathways and mechanisms were associated with calcium channel release, which is also the primary focus of future research. The qPCR results revealed that circRNA, miRNA, and mRNA expression levels were different. They may include novel noninvasive indicators for the early screening and prognostic prediction of HCM. CONCLUSION: In this study, we hypothesized a circRNA-miRNA-mRNA regulation network that is closely related to the progression and clinical outcomes of HCM and may contain promising biomarkers and treatment targets for HCM.
No takes yet. Share an insight, caveat, or question.
Gong et al. (2023) studied Hypertrophic cardiomyopathy (n=294). Hypertrophic cardiomyopathy vs. Normal tissues was evaluated on Differentially expressed circRNAs, miRNAs, and mRNAs. A circRNA-miRNA-mRNA regulatory network comprising two circRNAs, two miRNAs, and 30 mRNAs was identified as differentially expressed in hypertrophic cardiomyopathy and validated in a cellular model.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: